Prevalence of Inhibitors in a Population of 3435 Hemophilia Patients in France

 

PDF Download Buy Article Permissions and Reprints

Summary

A cooperative study between the 37 centers of the French Hemophilia Study Group was undertaken to establish the prevalence of inhibitor patients in the French hemophilia population. The prevalence reported in the literature varies widely from 3.6% to 17.5%. Some of the studies are dealing with a small number of patients and inhibitor patients are reported either to the total number of hemophiliacs or to the severely affected ones. The French study provided information concerning 3,435 hemophiliacs and showed a prevalence of 6.2% for the overall population. Prevalence of inhibitors was found to be 7% in the population of hemophilia A patients and 12.8% in the population of severely affected ones. The prevalence of inhibitors in the population of hemophilia B patients was 2% and 4% in the population of severely affected hemophilia B patients. The cooperative study also showed that 47.5% of inhibitors are detected before 10 years of age and that 82% of inhibitor patients are high responders. Analysis of inhibitor detection in patients under the age often showed that there was a peak in the population of 2 years old children. Although not comparable to the present study the high incidence of inhibitors with ultrapurified and recombinant FVIII reported in previously untransfused patient may be borne in mind.

• References

• 1 Strauss HS. Acquired circulating anticoagulants in hemophilia A. N Engl J Med 1969; 281: 866
  CrossrefPubMedGoogle Scholar
• 2 Brinkhous KM, Roberts HR, Weiss AE. Prevalence of inhibitors in hemophilia A and B. In: Thrombosis: Risk Factors and Diagnostic Approaches. Brinkhous KM, Owren PA, Hinnom S, Surgenor DM, Sherry S, Stengle JM. (eds) FK Schattauer Verlag; New York: 1972. pp 315-320
  Google Scholar
• 3 Kasper CK. Incidence and course of inhibitors among patients with classic hemophilia. Thromb Diath Haemorrh 1973; 30: 263-271
  PubMedGoogle Scholar
• 4 Rizza CR, Spooner RTD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-1980. Br Med J 1983; 286: 929-933
  CrossrefPubMedGoogle Scholar
• 5 Schwartzinger I, Pabinger I, Korninger C. et al Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987; 24: 241-245
  CrossrefPubMedGoogle Scholar
• 6 Kasper CK, Aledort LM, Counts RB. et al A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872
  PubMedGoogle Scholar
• 7 Langdell RD, Wagner RH, Brikhous KM. Effect of antihemophilic factor on one stage clotting test. J Lab Clin Med 1953; 41: 637-647
  PubMedGoogle Scholar
• 8 Allain JP, Frommel D. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood 1976; 47: 973-982
  PubMedGoogle Scholar
• 9 Burnouf T, Michalski C, Goudemand M, Huart JJ. Properties of a highly purified human plasma factor IX :C therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-232
  PubMedGoogle Scholar
• 10 Luscher JM, Salzman PM. Monoclate Study Group. Viral safety and inhibitor development associated with factor VIII: C ultra-purified from plasma in hemophilics previously unexposed to factor VIII: C concentrates. Semin Hematol 1990; 27 suppl. (02) 1-7
  PubMedGoogle Scholar
• 11 Kessler CM, Sachse K. Factor VIII:C inhibitor associated with monoclonal antibody purified FVIII concentrate. Lancet 1990; i: 335-1403
  PubMedGoogle Scholar
• 12 Schwartz RS, Abildgaard CF, Aledort LM. et al Human recombinant DNA-derived antihemophilic factor (Factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1800-1805
  CrossrefPubMedGoogle Scholar